Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 523-529

  Jung, Joo Young ^a   Kwon, Jung Hye ^a   Kim, Jung Han ^a   Song, Hun Ho ^a   Kim, Inho ^b   Lee, Keun Seok ^c   Kim, Hyo Jung ^a   Zang, Dae Young ^a,f   Ahn, Jin Seok ^d   Lee, Jung Ae ^e   Park, Young Iee ^c  

^a Hallym University   (South Korea)

^b Seoul National University   (South Korea)

^c National Cancer Center   (South Korea)

^d Seongyunkwan University   (South Korea)

^e Eulji University   (South Korea)

^f Hallym University Sacred Heart Hospital   (South Korea)

Author keywords

5 fluorouracil; Cisplatin; Gastric cancer; Leucovorin; Paclitaxel

Indexed keywords

CISPLATIN; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEFECT; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRANSAMINASEMIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SALVAGE THERAPY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PACLITAXEL; SALVAGE THERAPY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 62849091992     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000253     Document Type: Article

References (47)

1. Lee HJ, Yang HK and Ahn YO: Gastric cancer in Korea. Gastric Cancer 5: 177-182, 2002.
2. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
3. Wils JA, Klein HO, Wagener DJ, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827-831, 1991.
4. Schipper DL and Wagener DJ: Chemotherapy of gastric cancer. Anticancer Drugs 7: 137-149, 1996.
5. Okada Y, Anai H, Hattori T, Maehara Y, Nishimura J, Sugimachi K and Nawata H: Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer. Anticancer Drugs 2: 453-456, 1991.
6. Kim NK, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
7. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK and Chi CW: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14-18, 1996.
8. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R and Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274, 1998.
9. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET and Catalano G: Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9: 307-310, 1998.
10. Honecker F, Kollmannsberger C, Quietzsch D, et al: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13: 497-503, 2002.
11. Kim YH, Shin SW, Kim BS, et al: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85: 295-301, 1999.
12. Kollmannsberger C, Quietzsch D, Haag C, et al: A phase II study of paclitaxel, weekly, 24-h continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83: 458-462, 2000.
13. Lokich JJ, Sonneborn H, Anderson NR, Bern MM, Coco FV, Dow E and Oliynyk P: Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 85: 2347-2351, 1999.
14. Grem JL, Nguyen D, Monahan BP, Kao V and Geoffroy FJ: Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 58: 477-486, 1999.
15. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L and Kanz L: Paclitaxel and weekly 24-h infusion of 5-fluorouracil/ folinic acid in advanced gastric cancer. Semin Oncol 24: S19-96-S19-100, 1997.
16. Cho BC, Kim JH, Kim CB, Sohn JH, Choi HJ, Lee YC and Ahn JB: Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep 15: 621-627, 2006.
17. Ychou M, Astre C, Rouanet P, et al: A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer 32A: 1933-1937, 1996.
18. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the european organization for research and treatment of cancer gastro-intestinal tract cancer cooperative group. J Clin Oncol 18: 2648-2657, 2000.
19. Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989.
20. Zaniboni A, Barni S, Labianca R, et al: Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer: an italian group for the study of digestive tract cancer (GISCAD) report. Cancer 76: 1694-1699, 1995.
21. Louvet C, Andre T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002.
22. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267, 1997.
23. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B and Palacios P: Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 5: 142-147, 2002.
24. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006.
25. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK and Chung HC: A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology 70: 63-70, 2006.
26. Kim JG, Sohn SK, Song HS, et al: Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 60: 863-869, 2007.
27. Bokemeyer C, Lampe CS, Clemens MR, et al: A phase II trial of paclitaxel and weekly 24-h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8: 396-399, 1997.
28. Chao Y, Li CP, Chao TY, et al: An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer 95: 159-163, 2006.
29. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R and Philip PA: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 26: 37-41, 2003.
30. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO and Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe and effective regimen. Am J Clin Oncol 22: 580-586, 1999.
31. Vanhoefer U, Wilke H, Weh HJ, et al: Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 5: 850-851, 1994.
32. Johnson PW, Thompson PI, Seymour MT, Deasy NP, Thuraisingham RC, Slevin ML and Wrigley PF: A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 64: 603-605, 1991.
33. Yeh KH, Lu YS, Hsu CH, et al: Phase II study of weekly paclitaxel and 24-h infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer. Oncology 69: 88-95, 2005.
34. Omura GA, Brady MF, Look KY, et al: Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 21: 2843-2848, 2003.
35. Rowinsky EK, Jiroutek M, Bonomi P, Johnson D and Baker SD: Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 5: 767-774, 1999.
36. Belliveau JF, Posner MR, Ferrari L, et al: Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat Rep 70: 1215-1217, 1986.
37. Drewinko B, Brown BW and Gottlieb JA: The effect of cis- diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 33: 3091-3095, 1973.
38. Salem P, Hall SW, Benjamin RS, Murphy WK, Wharton JT and Bodey GP: Clinical phase I-II study of cis-dichlorodiammineplatinum(II) given by continuous lv infusion. Cancer Treat Rep 62: 1553-1555, 1978.
39. Salem P, Khalyl M, Jabboury K and Hashimi L: Cis-diamminedichloroplatinum (II) by 5-day continuous infusion: a new dose schedule with minimal toxicity. Cancer 53: 837-840, 1984.
40. Posner MR, Ferrari L, Belliveau JF, et al: A phase I trial of continuous infusion cisplatin. Cancer 59: 15-18, 1987.
41. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH and Chen KY: Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-h infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 76: 2186-2192, 1995.
42. Yoo CH, Noh SH, Shin DW, Choi SH and Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 87: 236-242, 2000.
43. Shah MA, Ramanathan RK, Ilson DH, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201-5206, 2006.
44. Weiss GB, Bunce H III and Hokanson JA: Comparing survival of responders and non-responders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials 4: 43-52, 1983.
45. Rothenberg ML, Carbone DP and Johnson DH: Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 3: 303-309, 2003.
46. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
47. Pinto C, Di Fabio F, Siena S, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510-517, 2007.